Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTG-100 for induction treatment of moderate to severe active ulcerative colitis
NL-OMON45322Phase 2Active, not recruiting
- Sponsor
- Protagonist Therapeutics, Inc.
- Start
- Nov 2017
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PTG-100 in autoimmune colitis (4 arms), sponsored by Protagonist Therapeutics, Inc. Primary endpoints: Clinical remission at Week 12 and At least 1 adverse event. Started Nov 2017; status: active, not recruiting.
02
Drugs
PTG-100
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON45322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45322.